ERBB2 and malaria: Chloroquine, a drug initially developed for the treatment of malaria in the 1930s, and recently tested as autophagy inhibitor in experimental models [75]–[77], may be used in future clinical trials in combination with Tzb, which should help clarify the importance of manipulating autophagy for enhancing the therapeutic benefit of Tzb in HER2-dependent breast carcinomas.